Abiraterone price may be discounted 40% for UK NICE approval

At the recent European Association of Urology (EAU) Annual Congress in Paris, one of the rumours was that the price of abiraterone (Zytiga) has been discounted 40% to the UK National Health Service (NHS) in order to obtain reimbursement approval from the National Institute for Health & Clinical Excellence (NICE).

As Sally notes in her video report from EAU 2012, if true, this has important commercial implications in the advanced prostate cancer market and potential new entrants such as MDV3100.

When looking at the prostate cancer competitive landscape and a market entry strategy, one of the issues to consider is reimbursement.

Regulatory approval to market a drug in Europe does not automatically mean it will be reimbursed or paid for by healthcare providers.   Abiraterone is a good example of this.

Another driver of price and reimbursement will be the cumulative cost of treatment for advanced prostate cancer. This is set to increase dramatically as new products such as MDV3100 and Alpharadin come to market, and their use moves from post-chemotherapy to the pre-chemotherapy setting.

You can gain more insights on some of the future challenges by watching Sally’s excellent conference coverage video from EAU 2012:

There is also  more information from EAU 2012 on Biotech Strategy Blog e.g. on Bayer’s Expanded Access Program for Alpharadin and an update on Millennium’s orteronel (TAK-700), a competitor to abiraterone.

Sally’s next conference video will be from the forthcoming American Assocation for Cancer Research (AACR) 2012 annual meeting that takes in place Chicago from March 31 – April 4.  We hope to see you there.

, , , , , , , , , , , , , , , ,

error: Content is protected !!